نتایج جستجو برای: cytogenetic risk groups

تعداد نتایج: 1591243  

2017
Maximilian Merz Anna Jauch Thomas Hielscher Elias K. Mai Anja Seckinger Dirk Hose Uta Bertsch Kai Neben Marc S. Raab Hans Salwender Igor W. Blau Hans-Walter Lindemann Ingo Schmidt-Wolf Christof Scheid Mathias Haenel Katja Weisel Hartmut Goldschmidt Jens Hillengass

To investigate cytogenetic evolution after upfront autologous stem cell transplantation for newly diagnosed myeloma we retrospectively analyzed fluorescence in situ hybridization results of 128 patients with paired bone marrow samples from the time of primary diagnosis and at relapse. High-risk cytogenetic abnormalities (deletion 17p and/or gain 1q21) occurred more frequently after relapse (odd...

2016
Seongjae Jang Jin Kyung Lee Minsu Cho Su San Yang Seung Hyun Kim Wan Tae Kim

BACKGROUND Industrial radiography is known to be one of the most vulnerable lines of work among the range of different radiation work. According to the relevant law in Korea, every worker registered in this work should check their blood cell counts every year in addition to their thermoluminescent dosimeter (TLD) doses. Since the law was enacted, however, few follow-up studies have been carried...

2013
Carolina B Belli

Myelodysplastic Syndromes (MDS) are a heterogeneous group of hematologic diseases characterized by refractory cytopenia(s) and variable risk of leukemic progression. Cytogenetic analysis is important in day-to-day clinical practice helping to define subgroups of MDS patients who share similarities in the course of the disease. There are recurring aberrations affecting chromosomes 5, 7, 8, and 2...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2002
Hagop M Kantarjian Susan O'Brien Jorge E Cortes Terry L Smith Mary Beth Rios Jianqin Shan Ying Yang Francis J Giles Deborah A Thomas Stefan Faderl Guillermo Garcia-Manero Sima Jeha William Wierda Jean-Pierre J Issa Steven M Kornblau Michael Keating Debra Resta Renaud Capdeville Moshe Talpaz

PURPOSE Imatinib mesylate, a specific Bcr-Abl tyrosine kinase inhibitor, has shown encouraging activity in chronic myelogenous leukemia (CML). EXPERIMENTAL DESIGN We treated 237 patients (median age, 50 years; age range, 18-82 years) with Philadelphia chromosome (Ph)-positive accelerated-phase CML with oral imatinib mesylate at daily doses of 400 mg (26 patients) or 600 mg (211 patients) and ...

Journal: :International Journal of Health Sciences (IJHS) 2022

Melatonin, as an endogenous hormone, is associated with the moderation of circadian rhythm. Besides controlling sleep-wake cycle, many physiological functions melatonin have been identified, such antioxidant, immune modulating, and anti-inflammatory. The current study was designed to estimate effect different doses on gene expression (TNF) in serum mitotic index (MI) bone marrow stem cells cyto...

Journal: :Blood 2012
Mathilde Lamarque Sophie Raynaud Raphael Itzykson Sylvain Thepot Bruno Quesnel Francois Dreyfus Odile Beyne Rauzy Pascal Turlure Norbert Vey Christian Recher Caroline Dartigeas Laurence Legros Jacques Delaunay Sorin Visanica Aspasia Stamatoullas Pierre Fenaux Lionel Adès

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience The International Prognostic Scoring System (IPSS), which is based on cytogenetics, BM blast percentage, and number of cytopenias, has played a major role in prognosis assessment in myelodysplastic syndrome (MDS) since its publication in 1997. The recently published revised I...

Journal: :Haematologica 2010
Dragana Milojkovic Emma Nicholson Jane F Apperley Tessa L Holyoake Pat Shepherd Mark W Drummond Richard Szydlo Marco Bua Letizia Foroni Alistair Reid Jamshid S Khorashad Hugues de Lavallade Katy Rezvani Christos Paliompeis John M Goldman David Marin

BACKGROUND Second-generation tyrosine kinase inhibitors induce cytogenetic responses in approximately 50% of patients with chronic myeloid leukemia in chronic phase in whom imatinib treatment has failed. However, it has not yet been established which of the patients in whom imatinib treatment fails are likely to benefit from therapy with second-generation tyrosine kinase inhibitors. DESIGN AN...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید